Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Susana Alvarez ContrerasfiledCriticalSusana Alvarez Contreras
Priority to MX2015013330ApriorityCriticalpatent/MX2015013330A/en
Publication of MX2015013330ApublicationCriticalpatent/MX2015013330A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present disclosure is related to a synergistic pharmaceutical composition in capsules, tablets or powder for oral administration, comprising a combination of a thiazolidinedione, such as pioglitazone and thiamine (Vitamin B1), or an analog, such as benfotiamine and its pharmaceutically acceptable salts, additionally to pharmaceutically acceptable carriers, excipients or preservatives, as well as the use of a combination for the preparation of a medicament with synergistic activity, for the formation inhibition of end products of the advanced glycation, prescribed for preventing diabetes mellitus complications, retinopathy, neuropathy, cardiomyopathy and diabetic nephropathy, as well as the comorbidities thereof.
MX2015013330A2015-09-182015-09-18Combined pharmaceutical composition for preventing diabetes mellitus complications.
MX2015013330A
(en)
Composition for preventing or treating tnf-related diseases, containing novel derivative as active ingredient, and method for inhibiting tnf activity by using same.
Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS